New trial tests filler for 'Ozempic Face'
NCT ID NCT07419854
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether Radiesse (calcium hydroxylapatite) injections can restore facial volume and improve skin quality in people who lose facial fullness from GLP-1 weight loss drugs like semaglutide. 48 adults starting GLP-1 therapy will be randomly assigned to receive either diluted Radiesse injections early or standard Radiesse after a 6-month wait. Researchers will use 3D imaging to measure changes in cheek and jowl volume, and doctors will rate aesthetic improvements.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Calcium hydroxylapatite (Radiesse) injections
- What this could lead to
- If it works, this could offer a cosmetic treatment to restore facial fullness and improve skin quality for people who lose facial volume from GLP-1 weight loss drugs.
- What could go wrong
- This is a small Phase 4 trial with only 48 participants, so results may not apply to everyone. As a cosmetic procedure, it carries risks like swelling, bruising, or uneven results.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GLP-1 RECEPTOR AGONIST-ASSOCIATED FACIAL VOLUME LOSS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
K. Kay Durairaj, MD, A Medical Corp.
RECRUITINGPasadena, California, 91105, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact